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Abstract 
Background:  Faecal immunochemical tests (FIT) for haemoglobin (f-Hb) have been 
recommended to assist in assessment of patients presenting in primary care with 
lower bowel symptoms.  The aim was to assess if, and which, additional variables 
might enhance this use of FIT. 
Methods:  FIT analysis has been a NHS Tayside investigation since December 
2015. During the first year, 993 patients attending colonoscopy were invited to 
complete a detailed questionnaire on demographic background, symptoms, smoking 
status, alcohol use, dietary fibre, red and processed meat intake, physical activity, 
sitting time, dietary supplement use, family history of colorectal cancer (CRC), 
adenoma (A), inflammatory bowel disease (IBD) and diabetes. Significant bowel 
disease (SBD) was classified as CRC, advanced A or IBD. 
Results:  470 (47.3%) invitees agreed to complete the questionnaire and 408 
(41.1%) did. Unadjusted odds ratios (OR) for the presence of SBD compared to 
undetectable f-Hb increased with increasing f-Hb and for f-Hb 10-49, 50-199, 200-
399 and ≥ 400 µg Hb/g faeces were 0.95 (95%CI: 0.16-5.63), 2.47 (0.5511.03), 6.30 
(1.08-36.65) and 18.90 (4.22-84.62) respectively.  Rectal bleeding and family history 
of polyps were the only other variables with statistically significant (p < 0.05) OR 
greater than 1.00, being 1.88 (1.13–3.17) and 2.93 (1.23–6.95) respectively. OR 
adjusted for all other variables showed similar associations, but only f-Hb and family 
history of polyps had significant associations.                   
Conclusions:  f-Hb is the most important factor to be considered when deciding 
which patients presenting in primary care with lower bowel symptoms would benefit 
most from referral for colonoscopy. 
Introduction 
The demand for colonoscopy has increased over recent years throughout the United 
Kingdom (UK). There are a number of plausible reasons for this, including (i) the 
positive publicity surrounding the four UK bowel screening programmes emphasising 
the benefits of detecting early disease, (ii) the information given to participants with 
negative screening test results that medical care should be sought if lower bowel 
symptoms are experienced between screening episodes, (iii) efforts encouraging all 
members of the public to seek care if symptoms arise, including the Be Clear on 
Cancer1, Detect Cancer Early2  and other local and regional campaigns and (iv) the 
influence of relevant charities and well-known individuals in the media. However, it is 
very well documented that diagnosis of significant bowel disease (SBD), which 
includes colorectal cancer (CRC), advanced adenoma (AA: any > 10 mm diam or 
three or more) and inflammatory bowel disease (IBD), is challenging, since there are 
often no specific symptoms and lower bowel symptoms are very common and mostly 
related to problems other than SBD.3,4 
In consequence, it would be of great value if a simple, relatively inexpensive 
investigation could be used to assist in the triage of patients presenting in primary 
care with lower bowel symptoms through assessing the risk of SBD and the priority 
for colonoscopy and, indeed, if this complex, expensive, time consuming and 
potentially risky investigation would be of any benefit to the individual. Currently, 
there is increasing evidence that faecal immunochemical tests (FIT) for haemoglobin 
(Hb) are of significant value in this clinical setting5,6 as well as in screening.7  Bowel 
cancer screening using FIT leads to a significant increase in uptake when compared 
with the previous card-based guaiac faecal occult blood tests (gFOBT)Interestingly, 
screening using FIT results in significantly increased uptake when compared with the 
previous card-based guaiac faecal occult blood tests (gFOBT),8,9 which also adds to 
the already high demands for colonoscopy. Recent reviews have detailed the 
evidence for FIT10,11 and the considerations, challenges and constraints involved in 
setting up a service for FIT12 have been documented recently to facilitate adoption of 
the recommendations of the National Institute for Health and Care Excellence in 
Diagnostic Guidance 30 (DG30).13 which This states that quantitative FIT are 
recommended for adoption in primary care to guide referral for suspected CRC in 
people without rectal bleeding who have unexplained symptoms but do not meet the 
criteria for a suspected cancer pathway referral outlined in the NICE guideline on 
suspected cancer (NG12).14  
It is known that FIT are imperfect as a diagnostic test and some cases of SBD would 
be missed using faecal haemoglobin concentration (f-Hb) alone.5,6,10,11  In part, this 
may be because a single cut-off f-Hb of 10 µg Hb/g faces is recommended13 in spite 
of the facts that f-Hb is higher in men than women and rises with age15,16 and 
deprivation.16,17  Moreover, signs and symptoms, even if they have low positive 
predictive value might add value.14 A number of risk-scoring systems have been 
developed18 and the COLONPREDICT19 and FAST Score20 approaches include f-Hb 
in their algorithms. However, these require additional information to the f-Hb. Thus, 
the aim of this study was to assess if, and which, additional variables to the f-Hb 
would enhance the use of FIT in the assessment of patients presenting in primary 
care with lower bowel symptoms. 
Methods 
Since December 2015, quantitative FIT service has been routinely available to NHS 
Tayside primary care. General practitioners (GP) were encouraged to request a FIT 
on all patients presenting in primary care in NHS Tayside with lower bowel 
symptoms, irrespective of age or symptoms. , comprising FIT kits were made up of 
written information detailing the rationale for measuring f-Hb, one specimen 
collection device (Kyowa-Medex Co., Ltd, Tokyo, Japan) and a pictorial patient 
instruction sheet. Practice nurses distribute a FIT kit to each patient selected for 
investigation of lower bowel symptoms. Patients are instructed to collect a single 
sample of faeces and return the FIT device immediately to the general practitioner’s 
(GP) surgery. The devices are then returned at room temperature via the GP routine 
sample collection service (a daily courier service) to Blood Sciences, Ninewells 
Hospital and Medical School, Dundee, and stored at 4oC prior to analysis: f-Hb is 
measured using a single HM-JACKarc (Kyowa Medex Co., Ltd., Tokyo, Japan) with , 
which has an analytical working range of 7 to 400 µg Hb/g faeces. Samples with 
results above the upper analytical limit are not diluted and re-assayed, but reported 
as ≥400 µg Hb/g faeces. Results with f-Hb ≥10 µg Hb/g faeces are defined as 
positive, this cut-off f-Hb being exactly as recommended in NICE DG30.13 The 
analyser is operated Monday-Friday and results reported electronically to the 
requesting GP to provide rapid result turnaround.  The laboratory is accredited by the 
United Kingdom Accreditation Service (UKAS) to ISO 15189 standards. Patients 
referred to endoscopy are investigated within six weeks of referral. The NHS Tayside 
endoscopy units participate in the accreditation scheme of the Joint Accreditation 
Group on Gastrointestinal Endoscopy. All findings were recorded on the endoscopy 
reporting system by the endoscopists. The diagnoses of CRC, AA and IBD were 
confirmed by a gastrointestinal pathologist: the nature of all biopsied or excised 
lesions and the stage of all CRC, using both Dukes’ and TMN systems were 
documented.  AA was defined as any adenoma (A) ≥ 10 mm maximum diameter 
and/or ≥ three A. The extent, severity and nature of any IBD was also recorded.  
For a period of one year, before undergoing further investigation, usually 
colonoscopy, all patients referred who had aw ith f-Hb result available were sent an 
invitation letter (from RJCS) with a study Patient Information Sheet enclosed. The 
letter was sent at least one week before the appointment to allow the patient 
sufficient time to decide whether or not to participate. Patients indicated their 
willingness to take part either via telephone, email, or a reply slip.  Patients who 
expressed an interest were approached by a member of the research team when 
attending the Endoscopy Units and, after giving consent, completed a short 
questionnaire based on validated question sets from a range of instruments which 
have been used successfully for data collection on a study of people attending family 
history clinics.21 The exclusion criteria were those patients who were deemed unfit 
and did not go forward for colonoscopy and those unable to give consent to 
complete the questionnaire. The domains and items were: demographic background, 
symptoms (categorised as rectal bleeding, change of bowel habit to looser motions, 
constipation, abdominal pain, weight loss, frequency of bowel movements) smoking 
status, alcohol intake, dietary fibre, red and processed meat intake, physical activity, 
sitting time, dietary supplement use (folate, vitamin D, fish oils), drug history 
(including prescribed aspirin and other anticoagulants) and family history of CRC, 
adenoma, or IBD.  In addition, participants were asked whether they have ever been 
diagnosed with diabetes.  Questions on diet were adapted from the University of 
Cambridge EPIC-Norfolk Food Frequency Questionnaire (FFQ).22 Data from the 
FFQ were converted into dietary fibre intake using McCance and Widdowson’s 
Composition of Food23 and Food Portion Sizes from the Food Standards Agency.24 
Dietary fibre was classified as a risk factor according to whether or not the patient 
met the recommendation of the Scottish Government Dietary Goals of 30 g per day 
of dietary fibre.25  Higher risk alcohol intake was identified using the Alcohol Use 
Disorders Identification Test Consumption questionnaire (AUDIT-C).26  Physical 
activity was measured using questions adapted from the short form International 
Physical Activity Questionnaire (IPAQ).27 Patients were considered as meeting 
physical activity guidelines if they undertook ≥ 5 days moderate intensity activity for ≥ 
30 minutes and/or walking for at least 30 minutes per day or 150 minutes per week.  
Height, weight and waist circumference were also measured and body mass index 
(BMI) calculated. 
Data on all specimens received for FIT were retrieved from the laboratory database 
and manually linked using the community health index (CHI) unique identifying 
number with the NHS Tayside electronic patient record and this study questionnaire 
database. 
All potential predictors of risk of SBD significant bowel disease, together with 
interactions between clinically important variables, were initially assessed using 
univariable logistic regression.  Age was converted to a categorical variable, as was 
f-Hb.  Factors identified as statistically significant predictors were included in a 
multivariate logistic regression and stepwise techniques applied. 
Results 
993 patients who were referred for colonoscopy were invited to complete the study 
questionnaire:  470 (47.3%) of these agreed to participate, but 62 participants did not 
complete the questionnaire, with reasons including non-attendance or cancellation of 
the colonoscopy appointment or time constraints in the Endoscopy Units.  
Demographic characteristics of the 408 patients who completed the study 
questionnaire and gave a wide spectrum of information on variables of interest are 
shown in Table 1. 
Table 1. Demographic characteristics of 408 patients completing the study 
questionnaire. 
Demographic Characteristic n (%) 
Gender 
 
 
Male 213 (52.2) 
 
Female 195 (47.8) 
Age category (years) 
 
 
<40 29 (7.1) 
 
40-49 36 (8.8) 
 
50-59 70 (17.2) 
 
60-69 127 (31.1) 
 
70-79 105 (25.7) 
 
≥ 80 41 (10.0) 
Scottish Index of Multiple Deprivation (SIMD) 2016 quintile 
 
SIMD 1 (most deprived) 58 (14.2) 
 
SIMD 2 52 (12.7) 
 
SIMD 3 93 (22.8) 
 
SIMD 4 122 (29.9) 
 
SIMD 5 (least deprived) 83 (20.3) 
Highest level of education completed 
 
 
Primary school 19 (4.7) 
 Secondary school 169 (41.4) 
 
University degree 61 (15.0) 
 
Postgraduate degree 27 (6.6) 
 
Other qualification after leaving school 132 (32.4) 
Employment 
 
 
Retired 233 (57.1) 
 
Employed full-time 104 (25.5) 
 
Employed part-time 37 (9.1) 
 
Unemployed 17 (4.2) 
 
Full-time student 1 (0.2) 
 
Other 16 (3.9) 
Marital Status 
 
 
Married/cohabiting 274 (67.3) 
 
Widowed/separated/divorced 88 (21.6) 
 
Single 45 (11.1) 
Ethnic group 
 
 
White 403 (98.8) 
 
Asian/Asian British 3 (0.7) 
 
Chinese 1 (0.2) 
 
Black or Black British 0 (0.0) 
 
Mixed 0 (0.0) 
 
Other 1 (0.2) 
 
72 patients had SBD detected at colonoscopy, comprising 18 CRC, 27 AA and 27 
new cases of IBD.  Table 2 shows the prevalence of risk factors and the results of 
initial univariate analysis performed to identify which factors showed association with 
SBD. 
Table 2. Prevalence of potential risk factors and number of patients with significant 
bowel disease (SBD: colorectal cancer, advanced adenoma or inflammatory bowel 
disease [IBD]) found at colonoscopy. 
Risk Factor (number with data available) 
No. with risk 
factor (%) 
No. with 
SBD (%) p-value 
Age, years (408) 
    
 
<40 
 
29 (7.1) 10 (34.5) 
0.601 
 
40-49 
 
36 (8.8) 7 (19.4) 
 
50-59 
 
70 (17.2) 10 (14.3) 
 
60-69 
 
127 (31.1) 21 (16.5) 
 
70-79 
 
105 (25.7) 17 (16.2) 
 
≥ 80 
 
41 (10.0) 6 (14.6) 
Gender (408) 
    
 
Male 
 
220 (53.9) 45 (20.5) 
0.139 
 
Female 
 
188 (46.1) 27 (14.4) 
Faecal haemoglobin concentration (113) 
   
 
Not detected 46 (40.7) 4 (8.7) 
<0.0001  
10 - 49 µg Hb/g faeces 24 (21.2) 2 (8.3) 
 
50 - 199 µg Hb/g faeces 20 (18.6) 4 (19.0) 
 
200 - 399 µg Hb/g faeces 8 (7.1) 3 (37.5) 
 
≥ 400 µg Hb/g faeces 14 (12.4) 9 (64.3) 
Symptoms 
    
 Iron deficiency anaemia (107) 32 (29.9) 7 (21.9) 0.651 
 
Rectal bleeding (405) 170 (42.0) 39 (22.9) 0.015 
 
Change to looser stool (407) 203 (49.9) 39 (19.2) 0.420 
 
Change to constipation (408) 143 (35.0) 21 (14.7) 0.354 
 
Abdominal pain (408) 164 (40.2) 30 (18.3) 0.798 
 
Weight loss (406) 
 
84 (20.7) 20 (23.8) 0.104 
 
Frequency of bowel movement (397) 
   
  
< 3 times/week 15 (3.8) 3 (20.0) 
0.342 
  
≤ 3 times/day 308 (77.6) 49 (15.9) 
  
> 3 times/day 74 (18.6) 17 (23.0) 
Current/regular medication (408) 
   
 
Aspirin 
 
74 (18.2) 10 (13.5) 0.329 
 
Anti-inflammatories 25 (6.1) 4 (16.0) 0.935 
 
Oral steroids 
 
22 (5.4) 7 (31.8) 0.123 
 
Warfarin 
 
15 (3.7) 0 (0.0) 0.143 
 
Clopidigrel 
 
22 (5.4) 4 (18.2) 0.826 
 
Statins 
 
121 (29.7) 19 (15.7) 0.598 
 
Vitamin D 
 
21 (5.2) 3 (14.3) 0.900 
 
Folate 
 
13 (3.2) 8 (61.5) 0.0001 
 
Fish oils 
 
32 (7.8) 5 (15.6) 0.943 
 
Multivitamins 27 (6.6) 3 (11.1) 0.509 
Previous colonoscopy (278) 216 (77.7) 41 (19.0) 0.359 
Family history (FDR) 
   
 
Colorectal cancer (404) 82 (20.3) 16 (19.5) 0.723 
 
Polyps (366) 
 
25 (6.8) 9 (36.0) 0.024 
 IBD (403) 
 
45 (11.2) 8 (17.8) 0.859 
 
Any family history of bowel disease 
(385) 127 (33.0) 28 (22.0) 0.181 
Diabetes (404) 
    
 
Type 1 
 
2 (0.5) 0 (0.0) 
 
 
Type 2 
 
51 (12.6) 7 (13.7) 0.565 
Diet 
      
 
Fruit & vegetables (< 5 portions/day) 
(408) 244 (59.8) 48 (19.7) 0.240 
 
Red meat (> 500g/week) (406) 21 (5.2) 6 (28.6) 0.281 
 
Processed meat (eats) (408) 361 (88.5) 64 (17.7) 0.933 
 
Fibre (< 30g/day) (407) 407 (100.0) 72 (17.7) N/A 
Alcohol (AUDIT-C Score ≥ 5) (381) 99 (26.0) 14 (14.1) 0.236 
Current smoker (405) 
 
58 (14.3) 8 (13.8) 0.502 
Low physical activity level* (395) 153 (38.7) 26 (17.0) 0.951 
Hours spent sitting/day (290) 
   
 
< 3 hours 
 
27 (9.3) 8 (29.6) 
0.098 
 
3 - 6 hours 
 
160 (55.2) 25 (15.6) 
 
≥ 6 hours 
 
103 (35.5) 14 (13.6) 
BMI ≥ 30.0 (376) 
 
105 (27.9) 15 (14.3) 0.376 
* ≥ 5 days moderate intensity activity for ≥ 30 minutes and/or walking for at least 30 mins per day OR 
150 minutes per week. 
 
 Elevated f-Hb, rectal bleeding and family history of polyps had statistically significant 
(p < 0.05) unadjusted OR > 1.00 and therefore showed association with an 
increased risk of SBD. Folate also showed a significant association, although the 
number of patients taking this supplement was small. Unadjusted and adjusted (for 
all other variables) OR for each of the variables for which OR were >1.00 for either 
are shown in Table 3. It should be noted that, after adjustment, rectal bleeding was 
no longer significantly associated with SBD, leaving only elevated f-Hb and family 
history of polyps. 
Table 3. Unadjusted and adjusted* odds ratios (OR) for significant bowel disease 
(SBD: colorectal cancer, advanced adenoma and inflammatory bowel disease). 
  
Unadjusted Adjusted 
  
OR (95% CI) p-value OR (95% CI) p-value 
Faecal haemoglobin concentration 
   
 
Not detected - - - - 
 
10 - 49 µg Hb/g faeces 0.95 (0.16 - 5.63)  0.959 1.99 (0.29 – 13.87) 0.488 
 
50 - 199 µg Hb/g faeces 2.47 (0.55 -11.03)  0.236 2.18 (0.40 – 11.84) 0.367 
 
200 - 399 µg Hb/g faeces 6.30 (1.08 - 36.65)  0.041 20.16 (2.16 – 187.94) 0.008 
 
≥ 400 µg Hb/g faeces 18.90 (4.22 - 84.62) < 0.001 25.65 (4.70 – 140.13) < 0.001 
Rectal bleeding 1.88 (1.13 – 3.17) 0.016 0.32 (0.07 - 1.49) 0.149 
Family history of polyps 2.93 (1.23 – 6.95) 0.021 8.21 (1.74 - 38.78) 0.008 
Folate 8.28 (2.62 – 26.11) < 0.001 7.29 (0.94 – 56.37) 0.057 
* adjusted for all other variables listed. 
Additional univariate analysis of risk factors was performed when also including low-
risk adenomas (LRA, n = 48) along with SBD.  As with analysis for SBD only, 
increasing f-Hb (p < 0.0001) and use of folate (p = 0.004) were significant predictors 
of SBD plus LRA.  However, in contrast to analysis for SBD only, rectal bleeding was 
not a statistically significant risk factor (p = 0.148), nor was a family history of polyps 
(p = 0.052).   
Discussion 
There are still many controversies regarding the use of FIT in assessment of patients 
presenting in primary care with lower bowel symptoms.10-12 There is no doubt that 
FIT can assist in the triage of such patients, but it is still unclear what other 
information might improve the diagnostic accuracy of this simple, inexpensive 
investigation. In this study, a large number of possibly useful variables have been 
investigated in a cohort of patients completing a comprehensive questionnaire. 
It was thought that age and male gender would be important variables associated 
with the finding of SBD since these are very relevant in the known incidence of SBD. 
Indeed, these factors, along with f-Hb, are the only variables included in the FAST 
Score,20 one of the risk scoring systems advocated, but not as yet proven to be of 
value in routine clinical practice. However, in this study, these variables did not have 
unadjusted, or adjusted for other variables, OR > 1.00 and of statistical significance 
(Table 3). Apart from rectal bleeding, which has been demonstrated to have higher 
positive predictive value than other symptoms associated with lower bowel 
disease,14 other symptoms were not significantly associated with the finding of SBD 
at colonoscopy. It is also important to note that even rectal bleeding did not have a 
predictive value that was independent of f-Hb. This confirms the findings in an earlier 
study in which three published evaluations of the use of FIT in assessment of the 
symptomatic undertaken in Scotland showed that the diagnostic accuracy of FIT was 
superior to the symptoms-based approach of the original 2015 NICE NG12 
guideline.28  Moreover, a very recent study from Spain 29 reports similar findings and 
states that referral of all patients should be guided by f-Hb irrespective of symptoms, 
rather than just in those not meeting the criteria for a suspected cancer pathway 
referral outlined in the 2017 NICE guidelines (NG12).14 Rectal bleeding was not 
significantly associated with risk when LRA was also assessed along with SBD.  This 
is perhaps to be expected given previous evidence that LRA are less likely to 
bleed.30 Another factor that was significant was, unsurprisingly, a family history of the 
presence of polyps: family history has been incorporated into another rather complex 
risk-scoring approach requiring incorporation of 11 variables.19 Other variables, 
including medication, diet, alcohol intake and activity were not associated with the 
finding of SBD. 
Folate intake was also statistically significantly associated with an increased risk of 
SBD, although only 13 patients reported regular use.  A very recent publication 
reports on long-term follow-up of 2,524 participants in a trial of folate and vitamin-
B12 supplementation versus placebo for prevention of osteoporotic fractures, 
reporting CRC risk to be significantly higher in those taking the supplements.31 It has 
previously been suggested in a large randomised controlled trial32 that that folate 
supplementation shows association with risk of AA, with elevated metabolised 
plasma folate acting as an inhibitor of natural killer cells cytokine inhibitors.33  
However, a systematic review and meta-analysis of studies on folate status and 
CRC risk showed no significant effect.34  Moreover, of the 8 cases of SBD in patients 
taking folate in this study, the majority had IBD rather than advanced neoplasia (one 
CRC, two AA and five new IBD cases).  When the 48 patients with LRA were 
included with SBD, only one patient with LRA reported taking a folate supplement.  
Therefore, although the association of folate with risk of SBD in our cohort is 
intriguing, speculation around this finding is limited by the sample size. 
However, the most important factor, with the highest statistical significance and OR 
is elevated f-Hb, that is, all f-Hb higher than the cut-off of 10 µg Hb/g faeces used in 
this .study.  In addition, the higher the f-Hb, the greater the OR. This is explained by 
the fact that it has been shown by a number of groups that f-Hb is directly related to 
the severity of lower bowel disease.30,35 In consequence, it may well be that risk 
scoring systems do not add significant value and that f-Hb should be considered as 
the most important criterion for referral from primary care for colonoscopy. 
This study has advantages over others in that many variables that could be 
associated with SBD have been examined by questionnaire administered by a 
member of the research team in person.  One limitation is that this is a relatively 
small study, which reflects the real difficulties in administering questionnaires to 
patients awaiting clinical investigations or treatment.  Another limitation is that, as 
shown in Table 1, the group that completed the questionnaire were generally older, 
less deprived and well-educated, retired, white and married: this cohort may not 
reflect the characteristics of other patients presenting in primary care in other 
locations.  In addition, the items in the questionnaire relate to current habits only and 
may, therefore, be subject to reverse causality. A further weakness of the study is 
that all patients who were included had already been referred for an endoscopy: 
however, this is a weakness of most studies on FIT in assessment of patients 
presenting in primary care with symptoms.36 
In conclusion, this study has demonstrated that f-Hb is the most important variable to 
consider when patients presenting in primary care are considered for referral for 
colonoscopy due to lower abdominal symptoms, although clinical impressions and 
the results of the full blood count may be of considerable value in this regard.10,11 
Further evaluations of published and new risk-scoring strategies involving other 
variables and more complex approaches to deciding on referral for colonoscopy are 
clearly required before they can be recommended for routine clinical use. 
Acknowledgements 
Lynne Taylor, Department of Blood Sciences, Ninewells Hospital and |Medical 
School, Dundee, made up and distributed FIT kits to GP practices. 
Alpha Laboratories Ltd, Eastleigh, Hants, are thanked for their support for the 
laboratory analyses. 
Declaration of interests 
CGF has undertaken paid consultancy with Immunostics Inc., Ocean, NJ, USA, and 
Kyowa-Medex Co. Ltd, Tokyo, Japan, and has received support for attendance at 
conferences from Alpha Labs Ltd, Eastleigh, Hants, UK.  Other authors have no 
interests to declare. 
Funding 
 
This study was funded by a grant from the Chief Scientist Office (grant number 
ASM/14/4). 
Ethical approval 
The study was approved by the North of Scotland Research Ethics Committee 
(reference number 15/NS/0101). 
Contributorship 
JD, RJCS, JAS, CM, AA and CGF conceived and planned the study. JAS 
supervised, and RMcC undertook, the FIT analyses. JD and LL undertook 
administration of the questionnaire. JD, RJCS and CGF performed the data analysis. 
JD, RJCS and CGF prepared drafts of the manuscript. All authors contributed 
significantly to the writing of the paper. 
Guarantor 
CGFJD. 
References 
1. Public Health England. Be Clear on Cancer. { HYPERLINK "https://www.nhs.uk/be-
clear-on-cancer/" } (accessed 09 November 2018) 
2. Scottish Government. Detect Cancer Early. 2015. { HYPERLINK 
"https://www.gov.scot/Topics/Health/Services/Cancer/Detect-Cancer-Early" } (accessed 09 
November 2018) 
3. Jellema P, van der Windt DA, Bruinvels DJ, et al.  Value of symptoms and 
additional diagnostic tests for colorectal cancer in primary care: systematic 
review and meta-analysis.  BMJ 2010; 340: c1269.  
4. Vega P, Valentín F, Cubiella J.  Colorectal cancer diagnosis: Pitfalls and 
opportunities. World J Gastrointest Oncol 2015; 7: 422 - 33.  
5. Westwood M, Corro Ramos I, Lang S, et al.  Faecal immunochemical tests to 
triage patients with lower abdominal symptoms for suspected colorectal cancer 
referrals in primary care: a systematic review and cost-effectiveness analysis. 
Health Technol Assess 2017; 21: 1 - 234. 
6. Westwood M, Lang S, Armstrong N, et al.  Faecal immunochemical tests (FIT) 
can help to rule out colorectal cancer in patients presenting in primary care with 
lower abdominal symptoms: a systematic review conducted to inform new NICE 
DG30 diagnostic guidance. BMC Med 2017; 15: 189. 
7. Young GP, Symonds EL, Allison JE, et al. Advances in fecal occult blood tests: 
the FIT revolution. Dig Dis Sci 2015; 60: 609 - 22.  
8. Steele RJ, McDonald PJ, Digby J, et al. Clinical outcomes using a faecal 
immunochemical test for haemoglobin as a first-line test in a national programme 
constrained by colonoscopy capacity. United European Gastroenterol J 2013; 
1:198 - 205. 
9. Moss S, Mathews C, Day TJ, et al. Increased uptake and improved outcomes of 
bowel cancer screening with a faecal immunochemical test: results from a pilot 
study within the national screening programme in England. Gut 2017; 66:1631 - 
44.  
10.  Steele RJC, Fraser CG. Faecal immunochemical tests (FIT) for haemoglobin for 
timely assessment of patients with symptoms of colorectal disease. In: Olsson L, 
Ed. Timely diagnosis of colorectal cancer. Cham: Springer; 2018.  
11. Fraser CG. Faecal immunochemical tests (FIT) in the assessment of patients 
presenting with lower bowel symptoms: Concepts and challenges. Surgeon. 
2018; 16: 302 - 308. 
12. Godber IM, Benton SC, Fraser CG. Setting up a service for a faecal 
immunochemical test for haemoglobin (FIT): a review of considerations, 
challenges and constraints. J Clin Pathol 2018; 71:1041 - 1045.  Oct 1. pii: 
jclinpath-2018-205047. doi: 10.1136/jclinpath-2018-205047. [Epub ahead of 
print]. 
13. National Institute for Health and Care Excellence. NICE Diagnostic Guidance DG 
30.  July, 2017. Quantitative faecal immunochemical tests to guide referral for 
colorectal cancer in primary care. { HYPERLINK "https://www.nice.org.uk/guidance/dg30" 
}  (accessed 09 November 2018). 
14. National Institute for Health and Care Excellence. NICE Guideline NG12; 
Suspected cancer: recognition and referral. July, 2017. { HYPERLINK 
"https://www.nice.org.uk/guidance/ng12" } (accessed 09 November 2018). 
15. McDonald PJ, Strachan JA, Digby J, Steele RJ, Fraser CG.   Faecal 
haemoglobin concentrations by gender and age: implications for population-
based screening for colorectal cancer. Clin Chem Lab Med 2011; 50: 935 - 40. 
16. Symonds EL, Osborne JM, Cole SR, et al. Factors affecting faecal 
immunochemical test positive rates: demographic, pathological, behavioural and 
environmental variables. J Med Screen 2015; 22:187 - 93. doi: 10.117 
17. Digby J, McDonald PJ, Strachan JA, et al.  Deprivation and faecal haemoglobin: 
implications for bowel cancer screening. J Med Screen 2014; 21: 95 - 7. 
18. Williams TG, Cubiella J, Griffin SJ, Walter FM, Usher-Smith JA. Risk prediction 
models for colorectal cancer in people with symptoms: a systematic review. BMC 
Gastroenterol 2016; 16: 63. 
19. Cubiella J, Vega P, Salve M, et al.  Development and external validation of a 
faecal immunochemical test-based prediction model for colorectal cancer 
detection in symptomatic patients. BMC Med 2016; 14: 128. 
20. Cubiella J, Digby J, Rodríguez-Alonso L, et al. The fecal hemoglobin 
concentration, age and sex test score: Development and external validation of a 
simple prediction tool for colorectal cancer detection in symptomatic patients. Int 
J Cancer 2017; 140: 2201 - 11 
21. Anderson AS, Caswell S, Macleod M, et al. Health behaviours and their 
relationship with disease control in people attending genetic clinics with a family 
history of breast or colorectal cancer. J Genet Council 2017; 26: 40 -51. 
22. University of Cambridge. EPIC-Norfolk Food Frequency Questionnaire (FFQ) 
Entry and Processing Documentation. { HYPERLINK 
"http://www.srl.cam.ac.uk/epic/epicffq/websitedocumentation.html" } (accessed 09 
November 2018). 
23.  McCance and Widdowson's The Composition of Foods, Sixth Summary Edition. 
Cambridge: Royal Society of Chemistry. Food Standards Agency, 2002. 
24. Food Portion Sizes, Third Edition. London: The Stationery Office. Food 
Standards Agency, 2002. 
25. The Scottish Government.  Revised Dietary Goals for Scotland - March 2016 { 
HYPERLINK "https://www.gov.scot/Resource/0049/00497558.pdf" }  (accessed 09 
November 2018). 
26.  Public Health England. Alcohol use disorders identification test consumption 
(AUDIT C), 2017. { HYPERLINK 
"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_da
ta/file/684826/Alcohol_use_disorders_identification_test_for_consumption__AUDIT_C_.pdf" } 
(accessed 09 November 2018). 
27. International Physical Activity Questionnaires (IPAQ) { HYPERLINK 
"https://sites.google.com/site/theipaq/home" } (accessed 09 November 2018). 
28. Quyn AJ, Steele RJ, Digby J, et al. Application of NICE guideline NG12 to the 
initial assessment of patients with lower gastrointestinal symptoms: not FIT for 
purpose? Ann Clin Biochem 2018; 55: 69 - 76.  
29. Herrero JM, Vega P, Salve M, Bujanda L, Cubiella J. Symptom or faecal 
immunochemical test based referral criteria for colorectal cancer detection in 
symptomatic patients: a diagnostic tests study. BMC Gastroenterol 2018; 18: 
155. 
30. Digby J, Fraser CG, Carey FA, et al.  Faecal haemoglobin concentration is 
related to severity of colorectal neoplasia. J Clin Pathol 2013; 66:415 - 9.  
31. Oliai Araghi S, Kiefte-de Jong JC, Dijk SCV, et al. Folic acid and vitamin-B12 
supplementation and the risk of cancer: long-term follow-up of the B-vitamins for 
the prevention of osteoporotic fractures (B-PROOF) trial. Cancer Epidemiol 
Biomarkers Prev. 2018; doi: 10.1158/1055-9965.EPI-17-1198. [Epub ahead of 
print]. 
32. Cole BF, Baron JA, Sandler RS, et al. Folic acid for the prevention of colorectal 
adenomas: a randomised clinical trial. JAMA 2007; 297: 2351 - 9. 
33. Troen AM, Mitchell B, Sorensen B, et al. Unmetabolized folic acid in plasma is 
associated with reduced natural killer cell cytotoxicity among postmenopausal 
women. J Nutr 2006; 136: 189 - 94.  
34. Moazzen S, Dolatkhah R, Tabrizi JS, et al. Folic acid intake and folate status 
and colorectal cancer risk: A systematic review and meta-analysis. Clin Nutr 
2017; 37: 1926 - 1934doi: 10.1016/j.clnu.2017.10.010. [Epub ahead of print]. 
35. Ribbing Wilén H, Blom J, Höijer J, Hultcrantz R. Fecal immunochemical test in 
colorectal cancer screening: Colonoscopy findings by different cut-off levels. J 
Gastroenterol Hepatol 2019; 34: 103 – 112. 2018 Jul 3. doi: 
10.1111/jgh.14373. [Epub ahead of print]. 
35.36. Fraser CG.  Faecal immunochemical tests for haemoglobin (FIT) in the 
assessment of patients with lower abdominal symptoms: current 
controversies. Gastroenterol Hepatol 2018 Nov 17. pii: S0210-
5705(18)30283-8. doi: 10.1016/j.gastrohep.2018.09.007. [Epub ahead of 
print] 
 
 
  
  
